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Abstract 50 
Introduction and Objective: This study aims to provide an update and compare perioperative 51 
outcomes and complications of Intracorporeal urinary diversion (ICUD) and extracorporeal 52 
urinary diversion (ECUD) following RARC from a multi-institutional, prospectively maintained 53 
database, the International Robotic Cystectomy Consortium (IRCC). 54 
Methods: A retrospective review of 2125 patients from 26 institutions was performed. ICUD 55 
was compared with ECUD Multivariate (stepwise variable selection) logistic regression models 56 
were fit to evaluate preoperative, operative, and postoperative predictors of receiving ICUD, 57 
operative time, high grade complications and 90-days readmissions after RARC.  58 
Results: 51% (n=1094) patients underwent ICUD in our cohort. ICUD patients demonstrated 59 
shorter operative times (357 vs 400 minutes, p<0.001), less blood loss (300 vs 350 ml, p<0.001), 60 
and fewer blood transfusions (4% vs 19%, p<0.001). ICUD patients experienced more high 61 
grade complications (13 vs 10%, p=0.02). Utilization of ICUD increased from 9% of all urinary 62 
diversions in 2005 to 97% in 2015. Complications after ICUD decreased significantly over time 63 
(p<0.001). On multivariable analysis, higher annual cystectomy volume (OR 1.02, 95% CI 64 
(1.01-1.03), p<0.002) and year of RARC 2013-2016 (OR 68, 95% CI 44-105, p<0.001) and ASA 65 
score <3 (OR 1.75, 95% CI 1.38-2.22, p<0.001) were associated with receiving ICUD. ICUD 66 
was associated with shorter operative time (27 minutes, p=0.001). 67 
Conclusion: Utilization of ICUD has increased over the past decade. Higher annual institutional 68 
volume of RARCs was associated with performing ICUD. ICUD was associated with shorter 69 
operative times. Although ICUD was associated with higher grade complications compared to 70 
ECUD, they decreased over time.  71 
 72 
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Introduction 73 
Utilization of robot-assisted radical cystectomy (RARCs) has witnessed a paramount 74 
increase in the past decade (1). While RARC has been associated with improved perioperative 75 
outcomes such as blood loss, hospital stay, and improved convalescence, much of the criticism 76 
has been attributed lack of tactile feedback and the longer operative time, especially with 77 
intracorporeal approach to urinary diversion and also with construction of a continent reservoir. 78 
Consequently, most surgeons performed a hybrid approach with extracorporeal construction of 79 
urinary diversion. 80 
Expertise and continuous refinement of the technique has cut down both operative times and 81 
costs (2). Consequently, operative time has been identified as a quality measure for surgical 82 
performance for RARC (3, 4). In a recent study, RARC and intracorporeal ileal conduit has been 83 
shown to be technically feasible and without jeopardizing outcomes (3, 5). On the other hand, 84 
intracorporeal neobladders are more technically challenging, time-consuming with steep learning 85 
curve and thereby they have been slower to adopt, and only confined to high volume academic 86 
institutions. Nevertheless, several techniques for intracorporeal neobladders have been recently 87 
described with promising functional and oncologic outcomes (6-9). 88 
Intracorporeal urinary diversion (ICUD) provides benefits in terms of a complete 89 
minimally invasive technique, including smaller incisions, reduced pain, decreased bowel-related 90 
complications, and reduced risk of third space losses and fluid imbalances (10, 11). This study 91 
aims to provide an update and compare perioperative outcomes and complications of ICUD and 92 
extracorporeal urinary diversion (ECUD) following RARC from a multi-institutional, 93 
prospectively maintained database, the International Robotic Cystectomy Consortium (IRCC). 94 
 95 
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Methods 96 
A retrospective review of 2432 patients from 29 institutions included in the IRCC 97 
database (I-97906) was performed. Patients who had missing data about the diversion approach 98 
or technique were excluded from the study. The final cohort comprised 2125 patients from 26 99 
institutions who were treated with RARC since 2005. Data were reviewed for age, gender, body 100 
mass index [BMI], American Society of Anesthesiologists [ASA] score, preoperative 101 
characteristics (neoadjuvant chemotherapy, prior abdominal surgery, and clinical staging), 102 
institutional volume, year of RARC, operative variables (type and technique of diversion, 103 
operative time, estimated blood loss, and blood transfusion), perioperative outcomes 104 
(complications, readmissions, hospital and intensive care unit stay), and pathologic outcomes 105 
(staging, lymph node yield and soft tissue surgical margins). Technique of RARC and urinary 106 
diversion, and follow up differed among institutions. ICUD was compared with ECUD in terms 107 
of complications, survival, and patterns of recurrence. 108 
Descriptive statistics were used to summarize the data. Univariable associations were 109 
statistically assessed using Wilcoxon Rank-Sum, Pearson Chi-square or Fisher’s Exact test. 110 
Univariate and multivariate (stepwise variable selection) logistic regression models were fit to 111 
evaluate preoperative, operative, and postoperative predictors of receiving ICUD, operative time, 112 
high grade complications and any readmission after RARC. The Kaplan Meier method was used 113 
to depict recurrence-free (RFS), disease specific (DSS) and overall survival (OS). Cox 114 
proportional hazards regression models were fit to evaluate predictors of survival outcomes. All 115 
tests were two-sided, with statistical significance defined as p≤0.05. All statistical analyses were 116 
performed using SAS software (version 9.4, SAS Institute Inc., Cary, NC). 117 
 118 
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Results 119 
Fifty-one percent (n=1094) patients underwent ICUD. Utilization of ICUD increased 120 
from 9% of all urinary diversions in 2005 to 97% in 2016, with a rate of increase of 11%/year 121 
(Figure 1). This increase has been primarily demonstrated for intracorporeal ileal conduits 122 
(increased from 2% in 2005 to 81% in 2016) and to a lesser extent for intracorporeal neobladders 123 
(from 7% in 2005 to 17% in 2016) (Figure 2). US institutions started to utilize ICUD more 124 
frequently in 2009 (22% of all diversions), and increased to 91% in 2015. In contrast, European 125 
institutions adopted ICUD earlier in their robotic experience (40% of all diversion in 2008 and 126 
reached 100% in 2016) (Figure 3). 127 
Compared to patients who received ECUD, ICUD patients included fewer patients with 128 
ASA score ≥3 (44% vs 53%, p<0.001), and received neoadjuvant chemotherapy more frequently 129 
(25% vs 17%, p<0.001). ICUD patients demonstrated shorter operative times (357 vs 400 min, 130 
p<0.001), less blood loss (300 vs 350 ml, p<0.001) and received blood transfusion less 131 
frequently (5% vs 13%, p<0.001). There was no significant difference in terms of receiving 132 
neobladders (21% vs 23%, p=0.32). ICUD patients experienced complications more often (57% 133 
vs 43%, p<0.001) especially within the first month after RARC (31 vs 19%, p<0.001). However, 134 
the incidence of high grade complications after ICUD decreased significantly over time (from 135 
25% in 2005 to 6% in 2015, p<0.001), and remained stable for ECUD (13% in 2005 and 14% in 136 
2015, p=0.76) (Figure 4). ECUD showed more overall readmissions (34% vs 26%, p=0.003) 137 
(Table 1). 138 
Both groups were comparable in terms of ≥pT3 disease (38% vs 39%, p=0.59), positive 139 
nodal disease (18% vs 19%, p=0.51), lymph node yield (11 vs 12, p=0.90) and positive soft 140 
tissue surgical margins (7% each, p=0.71). ECUD patients experienced more distant recurrences 141 
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(18% vs 14%, p=0.005), but less extrapelvic lymph node metastasis (1% vs 3%, p=0.01) and 142 
peritoneal carcinomatosis (0.3% vs 1.3%, p=0.01) (Table 2). 143 
On multivariable analysis, higher annual RARC volume (Odds ratio [OR] 1.02, 95% 144 
Confidence Interval [CI] (1.01-1.03), p=0.002), year of RARC 2013-2016 (OR 68, 95% CI 44- 145 
105, p<0.001) and ASA score<3 (OR 1.75, 95% CI 1.38-2.22, p<0.001) were associated with 146 
receiving ICUD (Table 3). On the other hand, shorter operative time was associated with older 147 
age (1 minute shorter for each 1 year increase in age, p<0.001), annual cystectomy volume (1 148 
minute shorter per 1 case increase in annual RARC volume, p=0.01), date of RARC (2013-2016 149 
vs 2005-2008) (23 minutes shorter, p=0.01) and ICUD (27 minutes shorter, p<0.001). On the 150 
other hand, BMI (estimate of 4 minutes longer for each 1 Kg/m2, p<0.001), ASA ≥3 (22 minutes 151 
longer, p<0.001) and receiving a neobladder (64 minutes longer, p<0.001) were associated with 152 
longer operative time (Table 4). 153 
History of prior abdominal surgery (OR 1.52 95% CI 1.06-2.15, p=0.02) was the only 154 
significant factor associated with high grade complications. Higher BMI (OR 1.05, 95% CI 1.02- 155 
1.07, p=0.0002), high grade complications (OR 2.22, 95 %CI 1.56-3.15, p<0.0001) were 156 
significantly associated with any readmission after RARC (Table 5). 157 
Both groups exhibited similar RFS and DSS (Log rank p= 0.97 and 0.80, respectively). 158 
However, ICUD experienced worse OS (85%, 62% and 49% vs 85%, 69% and 58% at 1, 3 and 5 159 
years, respectively) (log rank p=0.05) (Figure 5). For RFS, patients with ≥pT3 (HR 3.51, 95%CI 160 
2.76-4.45, p<0.001) and pN+ (HR 2.72, 95%CI 1.81-2.86, p<0.001) had worse RFS, while 161 
RARCs performed 2009-2013 (HR 0.72, 95% CI 0.57-0.92, p=0.03) demonstrated better RFS 162 
when compared to RARCs performed 2005-2009. For DSS, patients with higher lymph node 163 
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yield demonstrated marginal benefit (HR 0.97, 95% CI 0.96-0.99, p=0.01), while patients with 164 
positive soft tissue surgical margins (HR 1.66, 95% CI 1.07, 2.56, p=0.02), ≥pT3 (HR 5.63, 95% 165 
CI 3.89-8.13, p<0.001) and pN+ disease (HR 2.18, 95% CI 1.58-3.01, p<0.001) demonstrated 166 
worse DSS. For OS, high grade complications (HR 1.55, 95% CI 1.14-2.11, p=0.006), ASA≥3 167 
(HR 1.36, 95% CI 1.10-1.70, p=0.005), positive margins (HR 1.46, 95% CI 1.06-2,.00, p=0.02), 168 
≥pT3 (HR 3.52, 95% CI 2.73-4.54, p<0.001) and pN+ (HR 1.78, 95% CI 1.39-2.29, p<0.001) 169 
were associated with worse OS. Patients with neobladders had better OS (HR 0.49, 95% CI 0.30- 170 
0.70, p<0.001) (Table 6). 171 
Discussion 172 
Much of the criticism for ICUD has been attributed to the steep learning curve and longer 173 
operative time, especially if an orthotopic bladder substitute is planned. Our data shows that 174 
utilization of ICUD has increased over the past decade, reaching 97% in 2015 among IRCC 175 
members. This is contrast with prior reports that showed limited use of ICUD in the US (3% of 176 
RARCs) (12). Predictors of receiving ICUD were annual RARC volume, as well as cystectomy 177 
era (2013-2016) and ASA score < 3. It is notable that ICUD was adopted earlier in Europe when 178 
compared to the US (4). Prior reports showed that a stepwise approach to RARC and PLND 179 
allowed safe incorporation of ICUD (3). The technique of RARC, extended pelvic lymph node 180 
dissection (PLND) has been optimized, and as with experience in human-robot interaction, 181 
ICUD became more popular with development of multiple techniques for more complex 182 
intracorporeal neobladders (7, 9, 10, 13-15). A team approach combined with mentoring, 183 
especially during the early learning curve, will further reduce operative time and complications 184 
(16). Although there was no significant difference in the diversion type between ICUD and 185 
ECUD, the increase in utilization of ICUD has been primarily demonstrated for ileal conduits 186 
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(2% in 2005 to 81% in 2016) when compared to intracorporeal neobladders (from 7% in 2005 to 187 
17% in 2016). Intracorporeal neobladder is more technically demanding and this may explain 188 
this pattern. Whether the approach to urinary diversion affects the decision for urinary diversion 189 
choice is still unclear(17). 190 
With increased experience and comfort with the robotic platform, operative times for 191 
RARC have decreased over time (18). ICUD was associated with shorter operative time in this 192 
study in contrast to prior reports (11). This could be either due to increased comfort and 193 
experience with ICUD and flattening of the learning curve, or due to the additional time of 194 
undocking of the robot and preparing the patient for ECUD, which adds to the total operative 195 
time. Higher BMI, and neobladders may add to the complexity of RARC, with more time spent 196 
in port placement, careful dissection as well as LND (19, 20). Filson et al examined the different 197 
factors that may contribute to operative times and divided them into modifiable (such as extent 198 
of LND, diversion type and technique) and non-modifiable factors (such as age, gender in 199 
addition to institutional and surgeon factors) (21). They observed longer operative times with 200 
neobladders and with more extensive LNDs. Older age and the number of comorbidities were 201 
significantly associated with shorter operative times, which they explained by that surgeons 202 
anticipate higher anesthetic complications and tend to be faster in older and sicker patients. 203 
Female gender was also associated with longer operative times, which may be attributed to prior 204 
gynecologic procedures rather than a true gender-related difference (20). Higher annual RARC 205 
volume and more recent cystectomy era were associated with shorter operative time. More 206 
experience and flattening of the learning curve associated with more procedures performed 207 
would lead to cutting down of operative times. Similar to this study, higher surgical volume has 208 
been associated with shorter operative times for RC (21-23). 209 
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In an earlier report from IRCC (ICUD n=167, 18%), ICUD was associated with lower 210 
gastrointestinal and 90-day complication rates (11). The current study shows that patients who 211 
received ICUD had higher overall and high grade complications, especially within the first 212 
month after RARC. We believe that earlier experience was subject to patient selection bias. With 213 
increased utilization of ICUD and broadening of the patient selection, the actual burden of 214 
RARC, rather than ICUD, was observed (4). Interestingly, the incidence of high grade 215 
complications after ICUD decreased over time, while it remained stable for ECUD. Moreover, 216 
on multivariable analysis prior abdominal surgery was the only significant predictor of high 217 
grade complications. The presence of higher BMI and high grade complications were 218 
significantly associated with readmissions. The approach to urinary diversion (ICUD vs ECUD) 219 
was not a significant predictor of neither. About two-thirds of complications necessitating 220 
reoperations following RARC occur beyond 3 months of RARC. Therefore, it is important to 221 
report readmissions and complications beyond 3 months to avoid underestimation of the actual 222 
burden of the procedure (24). 223 
There was significant difference between both approaches in terms of RFS or DSS. In 224 
agreement with the robotic and open cystectomy literature, survival outcomes after cystectomy 225 
are mainly driven by disease-related factors, including pT stage, nodal status and positive 226 
surgical margins (25-28). Patients with ECUD experienced more distant recurrences when 227 
compared to ICUD. In agreement with a prior report from IRCC, the incidence of peritoneal 228 
carcinomatosis and port site recurrences are low (1% and 0.3%, respectively) (26). Despite the 229 
statistical difference between ICUD and ECUD in extrapelvic lymph node metastasis and 230 
peritoneal carcinomatosis, the small numbers limit any conclusions that can be made. Patients 231 
with ECUD experienced better OS at 3 and 5 years, likely because of the higher complication 232 
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rate associated with ICUD especially early in the ICUD experience. Nevertheless, diversion 233 
approach was not significantly associated OS. Patients who received neobladders had better OS 234 
likely because of patient selection bias rather than a true benefit of the urinary diversion type. 235 
Younger patients with fewer comorbidities and more favorable disease are more likely to be 236 
offered orthotopic bladder substitutes, and therefore more likely to have better survival outcomes 237 
(29). 238 
To our knowledge, this is largest reported series of ICUD. However, several limitations 239 
exist. The inherent limitations to retrospective analysis should be acknowledged. The variability 240 
among institutions in the IRCC in terms of surgical technique, institutional follow up protocols 241 
and pathology reporting, and lack of detailed complications and comorbidity data apart from that 242 
presented are other limitations (supplementary tables 1 and 2). IRCC includes mainly high 243 
volume institutions and experienced surgeons, which may limit the generalizability of the results. 244 
Conclusion 245 
Utilization of ICUD has dramatically increased over the past decade. Higher annual 246 
institutional volume of RARCs was associated with performing ICUD. ICUD was associated 247 
with shorter operative times. Although ICUD was associated with higher grade complications 248 
compared to ECUD, they decreased over time. More surgeons are incorporating ICUD as part of 249 
their RARC with standardization and evolution of the technique. 250 
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Table 1. Demographics, clinical characteristics and perioperative outcomes of patients who 
underwent ICUD versus ECUD. 
Preoperative parameters ECUD ICUD All p-
value 
N of patients (%) 1031 (49) 1094 (51) 2125 0.17 
Age at cystectomy, mean (SD) (yr) 68 (11) 67 (10) 67 (11) 0.03 
Gender, Males n (%) 827 (81) 780 (71) 1607 (76) < 0.001 
Body Mass Index, mean (SD) (kg/m2) 27.5 (5) 27.3 (5) 27.4 (5) 0.23 
ASA score >= 3, mean (SD) 484 (53) 337 (44) 821 (49) < 0.001 
Prior abdominal/pelvic surgery, n (%) 375 (41) 264 (45) 639 (43) 0.17 
Prior irradiation, n (%) 35 (6) 24 (5) 59 (6) 0.73 
Clinical T stage, ≥cT3, n (%) 149 (15) 118 (14) 267 (15) 0.36 
Neo-adjuvant chemotherapy, n (%) 175 (17) 254 (25) 429 (21) < 0.001 
Perioperative outcomes 
Type of diversion, neobladder, n (%) 236 (23) 231 (21) 467 (22) 0.32 
Operative time, median (IQR) (min) 400 (338-480) 357 (297-420) 371 (310-450) < 0.001 
Estimated blood loss, median (IQR) (ml) 350 (200-550) 300 (105-500) 300 (200-500) < 0.001 
Blood Transfusion, n (%) 135 (13) 50 (5) 185 (8) < 0.001 
Postoperative outcomes 
Any complication 441 (43) 623 (57) 1064 (50) < 0.001 
Clavien 3-5 99 (10) 141 (13) 240 (11) 0.02 
30-d complications 195 (19) 335 (31) 530 (25) < 0.001 
30-90 d complications 40 (4) 50 (5) 90 (4.2) 0.43 
Any readmission 147 (34) 213 (26) 360 (29) 0.003 
0-30-d readmissions, n (%) 56 (5) 57 (5) 113 (5.3) 0.82 
30-90-d readmissions, n (%) 34 (3) 46 (4) 80 (3.8) 0.27 
90-d mortality, n (%) 27 (3) 27 (3) 54 (3) 0.73 
Adjuvant chemotherapy, n (%) 156 (21) 116 (13) 272 (16) < 0.001 
Hospital stay, median (IQR) (days) 8 (6-12) 9 (7-14) 9 (7-13) < 0.001 
Intensive Care Unit stay, median (IQR) 
(days) 0 (0-1) 1 (0-1) 1 (0-1) < 0.001 
Follow up, median (months) (IQR) 17 (7-32) 11 (4-25) 13 (5-29) < 0.001 
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Table 2. Pathologic outcomes and sites of disease relapse  
Pathological outcomes  ECUD ICUD  All p-value 
Pathologic T stage, ≥pT3, 
n (%) 372 (39) 391 (38) 763 (39) 0.59 
Lymph node yield, mean  19 (12) 18 (11) 18 (11) 0.90 
N positive, n (%) 198 (19) 198 (18) 396 (19) 0.51 
Positive surgical margins, 
n (%) 74 (7) 74 (7) 148 (7) 0.71 
Any recurrence, n (%) 244 (24) 204 (19) 448 (19) 0.005 
Recurrence Site ECUD   ICUD All p-value 
Local recurrence, n (%) 101 (10) 107 (10) 208 (10) 1.00 
Pelvis 43 (4) 47 (4) 90 (4) 0.91 
Vagina 1 (0.1) 3 (0.3) 4 (0.3) 0.63 
Rectum 8 (0.8) 7 (0.6) 15 (0.6) 0.80 
Perineum 3 (0.3) 10 (0.9) 13 (0.9) 0.09 
Urethra 7 (0.7) 2 (0.2) 9 (0.2) 0.10 
Penile 0 (0) 2 (0.2) 2 (0.2) 0.50 
Neobladder/Conduit 1 (0.1) 3 (0.3) 4 (0.3) 0.63 
Kidney 1 (0.1) 3 (0.3) 4 (0.3) 0.63 
Multiple Local  8 (0.8) 13 (1) 21 (1) 0.39 
Unidentified site 42 (4) 29 (3) 71 (3) 0.07 
Distant recurrence, n (%) 188 (18) 151 (14) 339 (14) 0.005 
Nodal 14 (1) 33 (3) 47 (3) 0.01 
Lung 36 (4) 38 (4) 74 (4) 1.00 
Liver 16 (2) 18 (2) 34 (2) 1.00 
Bone 24 (2) 34 (3) 58 (3) 0.29 
Brain 1 (0.1) 6 (0.5) 7 (0.5) 0.13 
Abdominal wall 3 (0.3) 4 (0.4) 7 (0.4) 1.00 
Multiple distant 14 (1) 29 (3) 43 (2.7) 0.04 
Unidentified site 111 (11) 58 (5.3) 169 (5.3) <0.001 
Peritoneal carcinomatosis 3 (0.3) 14 (1.3) 17 (1.3) 0.01 
Port-site recurrence 0 (0) 3 (0.3) 3 (0.3) 0.25 
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Table 3. Stepwise multivariable logistic regression modeling predictors for receiving ICUD 
Parameter Odds Ratio 95%Confidence 
Interval 
p-value 
Annual RARC volume 1.02 (1.01, 1.03) 0.002 
Cystectomy Era (2009-2012) 
vs (2005-2008) 7.95 (5.6, 11.4) < 0.001 
Cystectomy Era (2013-2016) 
vs (2005-2008) 67.8 (43.8, 105) < 0.001 
ASA < 3 1.75 (1.38, 2.22) < 0.001 
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Table 4. Stepwise multivariable linear regression modeling predictors for longer operative time 
Parameter Estimate (min) p-value 
Intercept 376 <0 .001 
Age at Cystectomy -1 <0.001 
Body Mass Index 4 <0.001 
ASA ≥ 3 22 <0.001 
Average Cyst per Year -1 <0.001 
Cystectomy Era (2013-2016) 
[2005-2008] -23 0.01 
Neobladder 64 <0.001 
ICUD -27 <0.001 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 5. Stepwise multivariable regression modeling predictors for high grade complications and 
any readmission 
High grade complications Odds Ratio 95% Confidence 
Interval 
p-value 
Previous Abdominal Surgery 1.52 (1.08, 2.15) 0.02 
Any readmission Odds Ratio 95% Confidence 
Interval 
p-value 
Body Mass Index 1.05 (1.02, 1.07) 0.0002 
Clavien 3-5 2.22 (1.56, 3.15) < 0.0001 
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Table 6. Multivariable Cox proportional hazards modelling predictors of OS.  
RFS Hazard Ratio 95% Confidence 
Interval 
p-value 
Cystectomy era (2009-2013) 0.72 (0.57, 0.92) 0.03 
Cystectomy era (2013-2017) 0.85 (0.62, 1.18) 0.32 
pN+ 2.72 (1.81, 2.86) <0.001 
≥pT3 3.51 (2.76, 4.45) < 0.001 
DSS Hazard Ratio 95% Confidence 
Interval 
p-value 
Lymph node yield 0.97 (0.96, 0.99) 0.01 
Positive margins 1.66 (1.07, 2.56) 0.02 
pN+ 2.18 (1.58, 3.01) <0.001 
≥pT3 5.63 (3.89, 8.13) < 0.001 
OS Hazard Ratio 95% Confidence 
Interval 
p-value 
BMI 0.97 (0.95, 0.99) 0.003 
High grade complications 1.55 (1.14, 2.11) 0.006 
ASA≥3 1.36 (1.10, 1.70) 0.005 
Neobladder 0.49 (0.30, 0.70) <0.001 
Positive margins 1.46 (1.06, 2.00) 0.02 
pN+ 1.78 (1.39, 2.29) <0.001 
≥pT3 3.52 (2.73, 4.54) < 0.001 
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Figure 1: Diversion approach by year. ICUD increased from 9% in 2005 to 97% in 2015.  Increase of 
11% per year (p < 0.001) 
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Figure 2: Diversion type and approach by year 
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Figure 3: Diversion Approach by Region 
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Figure 4: High grade complications after ICUD decreased from 25% in 2005 to 6% in 2015 (decrease of 
2%/year, p<0.001). For ECUD, they remained stable (13% in 2006 to 14% in 2015 (p =0.76). 
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Figure 5: A. Kaplan Meier curves depicting RFS for patients who received ICUD vs ECUD 
after RARC (log rank p=0.97) 
 
IC: 
Interval  Failed  Censored  Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 152 439 818.5 1 0 
1 2 35 166 364 0.81 0.19 
2 3 9 116 188 0.74 0.26 
3 4 3 65 88.5 0.70 0.30 
4 5 1 27 39.5 0.68 0.32 
5 . 2 23 13.5 0.66 0.34 
EC: 
Interval  Failed Censored Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 128 272 770 1 0 
1 2 62 130 441 0.84 0.16 
2 3 17 115 256.5 0.72 0.28 
3 4 9 45 159.5 0.67 0.33 
4 5 1 46 105 0.63 0.37 
5 . 5 76 43 0.63 0.37 
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B. Kaplan Meier curves depicting DSS for patients who received ICUD vs ECUD after RARC 
(log rank p=0.80) 
 
IC: 
Interval  Failed Censored  Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 65 472 802 1 0 
1 2 36 191 405.5 0.92 0.08 
2 3 9 132 208 0.84 0.16 
3 4 5 70 98 0.80 0.20 
4 5 1 29 43.5 0.76 0.24 
5 . 0 28 14 0.74 0.26 
EC: 
Interval  Failed  Censored  Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 64 301 755.5 1 0 
1 2 33 162 460 0.92 0.08 
2 3 14 131 280.5 0.85 0.15 
3 4 9 53 174.5 0.81 0.19 
4 5 4 45 116.5 0.77 0.23 
5 . 4 86 47 0.74 0.26 
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C. Kaplan Meier curves depicting OS for patients who received ICUD vs ECUD after RARC 
(log rank p=0.046) 
 
IC: 
Interval  Failed Censored  Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 123 414 831 1 0 
1 2 70 157 422.5 0.85 0.15 
2 3 28 113 217.5 0.71 0.29 
3 4 15 60 103 0.62 0.38 
4 5 3 27 44.5 0.53 0.47 
5 . 1 27 14.5 0.49 0.51 
EC: 
Interval  Failed Censored Effective 
Sample 
Size 
Survival Failure 
[Lower, Upper)      
0 1 119 246 783 1 0 
1 2 50 145 468.5 0.85 0.15 
2 3 26 119 286.5 0.76 0.24 
3 4 15 47 177.5 0.69 0.31 
4 5 10 39 119.5 0.63 0.37 
5 . 17 73 53.5 0.58 0.42 
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Supplementary Table 1: RARCs/institution/year 
Institution 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
1 0 0 0 0 3 26 13 9 9 8 11 0 79 
2 0 0 2 2 8 2 0 0 0 0 0 0 14 
3 0 0 0 0 0 0 0 2 11 0 0 0 13 
4 2 16 1 2 11 5 11 7 37 0 0 0 92 
5 16 16 8 22 16 4 0 0 0 0 0 0 82 
6 0 0 1 12 2 0 0 0 0 0 0 0 15 
7 0 0 0 0 0 2 0 0 0 0 0 0 2 
8 0 0 1 8 9 8 0 0 0 0 0 0 26 
9 6 4 9 16 41 38 0 0 0 0 0 0 114 
10 3 5 16 8 13 3 8 14 4 0 0 0 74 
11 1 5 2 8 19 19 15 48 84 43 0 0 244 
12 0 0 0 0 0 0 2 8 6 2 0 0 18 
13 0 0 0 0 0 5 0 0 0 0 0 0 5 
14 0 0 0 0 0 0 1 0 0 0 0 0 1 
15 0 0 0 1 0 5 7 7 2 0 0 0 22 
16 12 6 15 14 4 1 0 0 0 0 0 0 52 
17 0 0 0 0 0 2 16 19 25 36 23 0 121 
18 3 30 33 47 42 44 36 45 45 45 46 36 452 
19 0 0 0 0 0 0 5 15 33 41 34 0 128 
20 0 0 8 5 36 36 21 15 0 3 3 0 127 
21 0 0 3 3 25 13 0 0 0 0 0 0 44 
22 0 4 4 3 7 3 0 0 0 0 0 0 21 
23 0 21 31 32 24 29 18 25 21 5 0 0 206 
24 0 0 0 18 29 42 19 1 0 0 0 0 109 
25 0 0 8 11 9 10 0 0 0 0 0 0 38 
26 0 0 6 8 7 5 0 0 0 0 0 0 26 
Total 43 107 148 220 305 302 172 215 277 183 117 36 2125 
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Supplementary Table 2: Comorbidities of patients who underwent ECUD vs ICUD 
Variable Name EC IC All (n)  All (%)  P Value 
Number of Patients 1031 (48.52) 1094 (51.48) 2125  0.172 
Myocardial Infarction  42 (10.99) 43 (6.96) 85 8.5 0.026 
Arrhythmia  40 (8.64) 45 (7.27) 85 7.86 0.407 
Congestive Heart Failure  10 (2.62) 44 (7.12) 54 5.4 0.002 
Peripheral Vascular Disease 20 (5.28) 39 (6.39) 59 5.97 0.471 
Carotid Disease  9 (2.37) 24 (4.04) 33 3.39 0.162 
Cardiovascular Disease 129 (22.87) 131 (21.41) 260 22.11 0.545 
Renal Insufficiency  27 (7.07) 61 (9.89) 88 8.81 0.127 
Dementia  2 (0.53) 7 (1.15) 9 0.91 0.495 
Asthma  13 (3.44) 26 (4.29) 39 3.96 0.506 
COPD  74 (13.17) 81 (13.28) 155 13.23 0.955 
Arthritis  49 (13) 60 (9.88) 109 11.08 0.13 
Peptic Ulcer Disease  24 (6.37) 31 (5.13) 55 5.61 0.414 
Diabetes Mellitus 149 (19.33) 135 (21.74) 284 20.4 0.267 
Stroke  20 (5.31) 20 (3.29) 40 4.06 0.119 
Liver Disease 45 (9.34) 13 (2.13) 58 5.32 < 0.001 
DVT/PE  12 (3.18) 34 (5.59) 46 4.67 0.082 
Hypertension  400 (59.88) 331 (53.56) 731 56.84 0.022 
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Key of Definitions: 
• Robot-assisted radical cystectomy (RARCs) 
• Intracorporeal urinary diversion (ICUD) 
• Extracorporeal urinary diversion (ECUD) 
• International Robotic Cystectomy Consortium (IRCC). 
• Body mass index [BMI],  
• American Society of Anesthesiologists [ASA] 
• Recurrence-free (RFS), disease specific (DSS) and overall survival (OS) 
• Odds ratio [OR]  
• 95% Confidence Interval [CI] 
 
